required ICU-level care. Amoxicillin & clavulanic acid (39.8%), clarithromycin (39.3%), and third-generation cephalosporins (32.5%) were the most frequent antimicrobials used to treat LRTIs. Of all LRTI patients treated with antimicrobials, 5.2% had pertinent culture data of which only one culture result was positive. Potentially inappropriate antimicrobial combinations were observed in 17.1% of total patients, 41.0% of ICU patients, and 6.2% of LRTI patients.
Conclusion:
In this first point-prevalence study of antimicrobial use in public hospitals in southern Sri Lanka, LRTI was the leading indication for antimicrobial use in all wards/units. Culture confirmation was low among LRTI patients, but broad-spectrum antimicrobial use was common. These findings highlight important targets for antimicrobial stewardship efforts. Background and Aims: Empyema is defined as bacterial invasion of the pleural cavity, which is a serious illness associated with considerable morbidity and mortality. Many guidelines recommend appropriate antibiotic treatment in accordance with pathogen. Unfortunately, about 30-40% of cases are only culture positive. The choice of antibiotic in the remaining case should be decided as the physician's clinical experience. The role of bronchoscopy in empyema is not clearly. Previous studies have focused on the distinction of structural abnormality through bronchoscopy. Bronchoscopy will provide more diagnostic information than routine microbiological cultures. However, there was no study about the yield of cultures through bronchoscopy in empyema. Therefore, the aim of our study was to assess the pathogen differentiation of bronchoscopy at empyema.
Methods: We retrospectively analyzed consecutive 153 patients with empyema who were admitted to the tertiary care hospital, South Korea between January 1, 2013 and April 30, 2018.
Results: The cultures of pleural effusion were identified pathogen in 34.6%. The most common pathogen was Streptococcus milleri group (8.5%), followed by anaerobic microbes (7.8%) and Enterobacteriaceae (5.2%). The cultures of sputum were identified pathogen in 14.4%. The most common pathogen was Enterobacteriaceae (5.2%), followed by Pseudomonas aeruginosa (2.6%) and Staphylococcus aureus (2.0%). Among all patients, bronchoscopy was performed in 60 patients. The bacterial isolated rate from bronchial washing was 30%. The most common pathogen was Staphylococcus aureus (10%), followed by Enterobacteriaceae (8.3%) and other streptococci (5%). The percentage of isolates with pleural effusion, sputum and bronchial washing was 45.8%, which was higher than that of pleural effusion alone (34.6%) or both pleural effusion and Sputum (41.8%). Results: Twenty-nine patients received complete treatment (completion group) and 29 patients had discontinuation of multiple drugs in treatment(discontinuation group). The number of discontinuation by adverse drug reaction was 21 patients (36.2%). BMI was significantly lower in the discontinuation group (17.7 kg/m 2 ) than in the completion group (19.9 kg/m 2 ). The reasons of discontinuation were as follows: adverse drug reaction (21 patients), complication disease (7 patients), acquisition of macrolide resistant (1 patient). The details of adverse drug reactions were as follows: allergy (8 patients), visual impairment (8 patients), general fatigue (3 patients), hepatitis (1 patient), and thrombocytopenia (1 patient). Median time of discontinuation of multiple drugs treatment due to allergy and visual impairment were 14.5 days and 434 days, respectively.
Conclusion

Conclusion:
In this study, the discontinuation rate of multiple drugs in treatment due to adverse drug reaction was similar to that in the previous report. In the discontinuation group, BMI was significantly reduced. It is considered that the increase of relative dose increased the risk of developing adverse drug reaction. We should pay attention especially to adverse drug reaction in low BMI patients with MAC lung disease. Background and Aims: Ventilator-associated pneumonia (VAP) is a common nosocomial infection following cardiac surgery and is associated with increase morbidity and mortality rate. Procalcitonin (PCT) is a promising biologic marker that will provide an early clue and accurate diagnosis in treatment of VAP. The aim of this study was to determine the utility of procalcitonin as an early biomarker of paediatric VAP in patients with congenital heart disease following cardiac surgery.
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